Roche Hopes To Gain Broad Market For Tecentriq In Adjuvant NSCLC
Interim ASCO Data Show Improvement in PD-L1 Expressors, All-Comers
An executive told Scrip the company hopes to target all-comers as well as PD-L1-positive patients.
You may also be interested in...
Ronapreve and Actemra for COVID-19 indications padded the top-line. Roche raised its financial outlook for the year to mid-single digit growth.
Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.
With big oncology losses largely in the rearview mirror, Roche is trying to sell investors on its next wave of cancer drugs; R&D overview pushes message of pipeline renewal.